Reporting the first successful treatment with oral Isavuconazole as primary antifungal agent following debridement, in an immunocompromised adult male with acute invasive fungal sinusitis involving multiple simultaneous fungal species. His comorbidities were retroviral and COVID infections, uncontrolled diabetes, ketoacidosis, and renal failure. A two-year follow-up revealed no recurrence.